MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

Your dad added you as a joint account owner on his bank account, and everything was okay. Well, until his passing! The ...

NEW RELIC NOW?New Relic, the Intelligent Observability company, announced Logs Intelligence, a series of AI-strengthened capabilities that automate the time and effort required to reduce mean time to ...

DeepL, a leading global AI product and research company, today announced two major business innovations for knowledge workers - DeepL Agent and Customization ...